Funds are being requested to purchase a NanoSPECT small-animal SPECT (single-photon emission computed tomography) and CT (transmission computed tomography) scanner (Bioscan, Washington, DC) for non-invasively and longitudinally monitoring cancer and other disease processes, trafficking of cancer, immune, and stem cells, cellular responses to therapy and other interventions, genetic pathway expression, and tumor targeting and biodistribution of new radio diagnostic and radio therapeutic agents in small-animal (i.e. mouse and rat) models. This state-of-the-art instrument, to be installed in our existing Small-Animal Imaging Core Facility, will be a critical, broadly used addition to the pre-clinical and translational oncology research program at Memorial Sloan-Kettering Cancer Center (MSKCC). Like our existing (but technically limited and outdated) microSPECT-microCT system, the X- SPECT, the NanoSPECT will play a critical role in the development of novel radio diagnostic and radio therapeutic agents (including """"""""anti-tumor"""""""" antibodies and other immune constructs), gene imaging (i.e. reporter gene) systems and in vivo imaging of various cellular and molecular-genetic processes critical to our understanding of the natural history of cancer and its response to various therapies. Funds for a new, far more functional microSPECT-microCT system, the NanoSPECT, are therefore urgently requested to enhance and expand our in vivo radionuclide imaging capabilities and to provide more quantitatively reliable three-dimensional (tomographic) in vivo radionuclide imaging capability. Among the critical advantages of the NanoSPECT over our outdated X-SPECT are: (1) substantially higher sensitivity, yielding higher quality, more quantitatively accurate images in shorter imaging times;(2) the capability of performing whole-body ultra-high-resolution pinhole SPECT studies, providing whole-body biodistribution data and recognizable anatomic information in a single study;and (3) the capability to image high-energy single- photon emitters such as iodine-131 (131I), a widely used and important """"""""therapeutic"""""""" radionuclide not image-able with the X-SPECT. In addition to numerous funded projects with scientific plans in place to use the NanoSPECT, our Facility and our Center have well-established technical and scientific expertise to fully and immediately utilize this instrument upon its installation and a highly efficient administrative and financial infrastructure in place to support and maintain this instrument and its effective use long-term.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Biomedical Research Support Shared Instrumentation Grants (S10)
Project #
1S10RR028889-01
Application #
7838795
Study Section
Special Emphasis Panel (ZRG1-SBIB-U (31))
Program Officer
Levy, Abraham
Project Start
2011-09-01
Project End
2012-08-31
Budget Start
2011-09-01
Budget End
2012-08-31
Support Year
1
Fiscal Year
2011
Total Cost
$907,340
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Pankov, Dmitry; Sjöström, Ludvig; Kalidindi, Teja et al. (2017) In vivo immuno-targeting of an extracellular epitope of membrane bound preferentially expressed antigen in melanoma (PRAME). Oncotarget 8:65917-65931
Lee, Jason T; Zhang, Hanwen; Moroz, Maxim A et al. (2017) Comparative Analysis of Human Nucleoside Kinase-Based Reporter Systems for PET Imaging. Mol Imaging Biol 19:100-108
Russell, James; Pillarsetty, Nagavarakishore; Kramer, Robin M et al. (2017) In Vitro and In Vivo Comparison of Gemcitabine and the Gemcitabine Analog 1-(2'-deoxy-2'-fluoroarabinofuranosyl) Cytosine (FAC) in Human Orthotopic and Genetically Modified Mouse Pancreatic Cancer Models. Mol Imaging Biol 19:885-892
Cheal, Sarah M; Xu, Hong; Guo, Hong-Fen et al. (2016) Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity ??Y- or ¹??Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates. Eur J Nucl Med Mol Imaging 43:925-37
Thorek, Daniel L J; Watson, Philip A; Lee, Sang-Gyu et al. (2016) Internalization of secreted antigen-targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis. Sci Transl Med 8:367ra167
Thorek, Daniel L J; Kramer, Robin M; Chen, Qing et al. (2015) Reverse-Contrast Imaging and Targeted Radiation Therapy of Advanced Pancreatic Cancer Models. Int J Radiat Oncol Biol Phys 93:444-53
Eveno, Clarisse; Mojica, Kelly; Ady, Justin W et al. (2015) Gene therapy using therapeutic and diagnostic recombinant oncolytic vaccinia virus GLV-1h153 for management of colorectal peritoneal carcinomatosis. Surgery 157:331-7
Moroz, Maxim A; Zhang, Hanwen; Lee, Jason et al. (2015) Comparative Analysis of T Cell Imaging with Human Nuclear Reporter Genes. J Nucl Med 56:1055-60
Doran, Michael G; Spratt, Daniel E; Wongvipat, John et al. (2014) Cabozantinib resolves bone scans in tumor-naïve mice harboring skeletal injuries. Mol Imaging 13:
Cheal, Sarah M; Xu, Hong; Guo, Hong-fen et al. (2014) Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complex. Mol Cancer Ther 13:1803-12

Showing the most recent 10 out of 11 publications